ENAapplication/xmlftp://primaryOK200GenomicsNCIhttps://www.ebi.ac.uk/ena/browser/view/PRJNA957548Homo sapiensWomen with breast cancers that overexpress HER2 are at greater risk for disease progression and death than women whose tumors do not overexpress HER2. Trastuzumab, a recombinant humanized monoclonal antibody against the extracellular domain of the HER2 protein blocks downstream signaling of HER2 and substantially improves the efficacy of chemotherapy in women with metastatic and early-stage HER2-positive breast cancers. Because resistance to trastuzumab eventually results in progressive disease in the metastatic setting and contributes to recurrence following adjuvant trastuzumab-based therapy, it is important to develop agents other than trastuzumab that target HER2 signaling through different mechanisms of action. Lapatinib is an oral, small molecule, dual tyrosine kinase inhibitor of... (for more see dbGaP study page.)ENAfalsePrediction of Resistance and Sensitivity to HER2 Targeted Therapy in the Neoadjuvant SettingPrediction of Resistance and Sensitivity to HER2 Targeted Therapy in the Neoadjuvant Setting2025-09-242023-07-01PRJNA9575489606